Publications by authors named "Massimo Breccia"

100Publications

Prognostic Significance of Transcript-Type in Chronic Myeloid Leukemia.

Mediterr J Hematol Infect Dis 2020 1;12(1):e2020062. Epub 2020 Sep 1.

Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto 1, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4084/MJHID.2020.062DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7485470PMC
September 2020

The advantages and risks of ruxolitinib for the treatment of polycythemia vera.

Expert Rev Hematol 2020 Sep 11:1-6. Epub 2020 Sep 11.

Hematology, Department of Translational and Precision Medicine, Sapienza University Azienda Policlinico Umberto 1 , Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2020.1816819DOI Listing
September 2020

Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab.

Ann Hematol 2020 Aug 27. Epub 2020 Aug 27.

Hematology, Department of Translational and Precision Medicine, Azienda Ospedaliera Policlinico Umberto 1, Sapienza University, Via Benevento 6, 00161, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04236-7DOI Listing
August 2020

Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience.

Ann Hematol 2020 Oct 19;99(10):2405-2416. Epub 2020 Aug 19.

Hematology, Department of Translational and Precision Medicine, Azienda Ospedaliera Policlinico Umberto I, Sapienza University, Via Benevento 6, 00161, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04217-wDOI Listing
October 2020

Direct oral anticoagulants in patients with hematologic malignancies.

Hematol Oncol 2020 Jun 26. Epub 2020 Jun 26.

Hematology, Departement of Translational and Precision Medicine, "Sapienza", University of Rome, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2770DOI Listing
June 2020

Younger age at diagnosis of acute promyelocytic leukaemia is associated with better long-term cognitive functioning.

Br J Haematol 2020 Sep 18;190(5):e304-e307. Epub 2020 Jun 18.

Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16877DOI Listing
September 2020

Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients.

Ann Hematol 2020 May 28. Epub 2020 May 28.

Hematology, Department of Precision and Translational Medicine, Policlinico Umberto 1, Sapienza University, Via Benevento 6, 00161, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04096-1DOI Listing
May 2020

Therapeutic strategies in low and high-risk MDS: What does the future have to offer?

Blood Rev 2020 Mar 31:100689. Epub 2020 Mar 31.

Hematology, Department of Translational and Precision Medicine, Sapienza University, Az. Policlinico Umberto 1, Rome, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2020.100689DOI Listing
March 2020

Imatinib improved the overall survival of chronic myeloid leukemia patients in low- and middle-income countries: A therapeutic goal has been reached.

Authors:
Massimo Breccia

EClinicalMedicine 2020 Feb 18;19:100277. Epub 2020 Feb 18.

Hematology, Department of Translational and Precision Medicine, Sapienza University, Azienda Policlinico Umberto 1, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eclinm.2020.100277DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7030979PMC
February 2020

Hemorrhagic Complications in Patients Treated With Azacitidine and Direct Oral Anticoagulants.

Am J Ther 2020 02 17. Epub 2020 Feb 17.

Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MJT.0000000000001105DOI Listing
February 2020

First-line dasatinib discontinuation in chronic myeloid leukaemia: another step towards an "operational cure".

Lancet Haematol 2020 Mar 21;7(3):e182-e183. Epub 2020 Jan 21.

Hematology, Department of Translational and Precision Medicine, Sapienza University, Azienda Policlinico Umberto 1, Rome 00161, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(19)30251-0DOI Listing
March 2020

Treatment-free remission in chronic myeloid leukemia.

Clin Adv Hematol Oncol 2019 Dec;17(12):686-696

Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
December 2019

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.

N Engl J Med 2019 12;381(24):2315-2326

From the South Australian Health and Medical Research Institute and the University of Adelaide, Adelaide, SA, Australia (T.P.H., D.Y., D.M.R.); Memorial Sloan Kettering Cancer Center, New York (M.J.M., M.S.T., J.H.P.); University of Texas M.D. Anderson Cancer Center, Houston (J.E.C.); Kobe University Graduate School of Medicine, Kobe (H.M.), and the National Cancer Center Hospital East, Chiba (Y.M.) - both in Japan; Hôpital Saint-Louis, Paris (D.R.), and the University of Bordeaux, Bordeaux (F.-X.M.) - both in France; Dana-Farber Cancer Institute, Boston (D.J.D.); Sapienza University, Rome (M.B.); Singapore General Hospital, Singapore (Y.-T.G.); University of Michigan Comprehensive Cancer Center, Ann Arbor (M.T.); Universitätsklinikum Jena, Jena (A.H.), Charité Hospital, Berlin (P.C.), and the Department for Hematology-Oncology, Goethe University Hospital, Frankfurt am Main (F.L.) - all in Germany; University of Cardiff, Cardiff, United Kingdom (O.O.); Veterans Affairs Portland Health Care System (M.C.H.) and Oregon Health and Science University Knight Cancer Institute (M.C.H., B.J.D.), Portland; Hospital de la Princesa and Instituto de Investigación Sanitaria Princesa, Madrid (J.L.S.); Huntsman Cancer Institute, University of Utah, Salt Lake City (M.W.N.D.); Amsterdam University Medical Centers, VU University Medical Center, Amsterdam (J.J.W.M.J.); Novartis Pharma, Basel, Switzerland (D.H., Y.D., C.M., F.H.-P., K.G.V.); and Seoul St. Mary's Hematology Hospital, Catholic University of Korea, Seoul, South Korea (D.-W.K.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1902328DOI Listing
December 2019

The role of cladribine in acute myeloid leukemia: an old drug up to new tricks.

Leuk Lymphoma 2020 03 22;61(3):536-545. Epub 2019 Nov 22.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1672060DOI Listing
March 2020

Mechanisms and clinical course of cardiovascular toxicity of cancer treatment II. Hematology.

Semin Oncol 2019 12 11;46(6):403-407. Epub 2019 Nov 11.

Department of Medicine, Campus Bio-Medico University, Rome, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2019.10.005DOI Listing
December 2019

The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review.

Bone Marrow Transplant 2020 Apr 18;55(4):708-716. Epub 2019 Sep 18.

Section of Hematology, Department of Medicine, University of Verona, Verona, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0683-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113188PMC
April 2020

A journey through infectious risk associated with ruxolitinib.

Br J Haematol 2019 11 29;187(3):286-295. Epub 2019 Aug 29.

Department of Haematology Oncology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16174DOI Listing
November 2019

Maintenance therapy in AML: The past, the present and the future.

Am J Hematol 2019 11 11;94(11):1254-1265. Epub 2019 Sep 11.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25620DOI Listing
November 2019

Digital droplet PCR at the time of TKI discontinuation in chronic-phase chronic myeloid leukemia patients is predictive of treatment-free remission outcome.

Hematol Oncol 2019 Dec 5;37(5):652-654. Epub 2019 Aug 5.

Hematology, Department of Translational and Precision Medicine, University 'Sapienza' and Policlinico Umberto 1, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2650DOI Listing
December 2019

Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice.

Ann Hematol 2019 Aug 5;98(8):1919-1925. Epub 2019 Jun 5.

Hematology, Department of Precision and Translational Medicine, Azienda Ospedaliera Policlinico Umberto I, Sapienza University, Via Benevento 6, 00161, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03724-9DOI Listing
August 2019

Can Chronic-Phase Chronic Myeloid Leukemia Patients Achieve Optimal and Durable Responses after Two Failed TKI Treatments? Real-World Evidence Data.

Authors:
Massimo Breccia

Acta Haematol 2019 21;142(2):61-63. Epub 2019 May 21.

Hematology, Department of Translational and Precision Medicine, Policlinico Umberto 1, "Sapienza" University, Rome, Italy,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000496449DOI Listing
February 2020

Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life.

Ann Hematol 2019 Aug 11;98(8):1891-1904. Epub 2019 May 11.

Hematology, Department of Translational and Precision Medicine, Sapienza University, Via Benevento 6, 00161, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03706-xDOI Listing
August 2019

Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia.

Ther Adv Hematol 2019 1;10:2040620719826444. Epub 2019 Mar 1.

Haematology, Department of Cellular Biotechnologies and Haematology, Azienda Ospedaliera, Policlinico Umberto I, Sapienza University, Via Benevento 6, 00161, Roma, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2040620719826444DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399752PMC
March 2019

Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemia.

Expert Rev Hematol 2019 02 7;12(2):81-87. Epub 2019 Jan 7.

a Hematology, Department of Cellular Biotechnologies and Hematology , Policlinico Umberto 1, Sapienza University , Rome , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1562332DOI Listing
February 2019

Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events.

Ann Hematol 2018 Oct 27;97(10):1803-1808. Epub 2018 May 27.

Division of Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, Sapienza University, Via Benevento 6, 00161, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-018-3375-9DOI Listing
October 2018

Novel tyrosine-kinase inhibitors for the treatment of chronic myeloid leukemia: safety and efficacy.

Expert Rev Hematol 2018 04 13;11(4):301-306. Epub 2018 Mar 13.

a Department of Cellular Biotechnologies and Hematology , Policlinico Umberto 1, 'Sapienza' University , Rome , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1451322DOI Listing
April 2018

Current Information and Recommendations on the Discontinuation of TKI Inhibitors in Chronic Myeloid Leukemia.

Curr Oncol Rep 2018 03 6;20(3):23. Epub 2018 Mar 6.

Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto 1, 'Sapienza' University, Via Benevento 6, 00161, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-018-0669-yDOI Listing
March 2018

Low-Dose Ponatinib in Intolerant Chronic Myeloid Leukemia Patients: A Safe and Effective Option.

Clin Drug Investig 2018 05;38(5):475-476

Department of Cellular Biotechnologies and Hematology, University "La Sapienza" of Rome, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40261-018-0623-7DOI Listing
May 2018

Physicians' attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients.

Health Qual Life Outcomes 2017 Oct 18;15(1):204. Epub 2017 Oct 18.

Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12955-017-0788-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648464PMC
October 2017

Ponatinib: A Review of Efficacy and Safety.

Curr Cancer Drug Targets 2018 ;18(9):847-856

Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568009617666171002142659DOI Listing
September 2019

Timing and deepness of response to tyrosine kinase inhibitors as a measure of potential treatment discontinuation in chronic myeloid leukemia patients managed in the real-life.

Am J Hematol 2017 12 19;92(12):E668-E670. Epub 2017 Oct 19.

Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto 1, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.24916DOI Listing
December 2017

The Eutos long-term survival score accurately predicts the risk of death in chronic myeloid leukaemia patients treated outside of clinical trials.

Am J Hematol 2017 Dec 19;92(12):E661-E664. Epub 2017 Oct 19.

Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto 1, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ajh.24913
Publisher Site
http://dx.doi.org/10.1002/ajh.24913DOI Listing
December 2017

Diagnostic and prognostic cytogenetics of chronic myeloid leukaemia: an update.

Expert Rev Mol Diagn 2017 11 26;17(11):1001-1008. Epub 2017 Sep 26.

a Hematology, Department of Cellular Biotechnologies and Hematology , Sapienza University , Rome , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737159.2017.1383156DOI Listing
November 2017